Spots Global Cancer Trial Database for nf1
Every month we try and update this database with for nf1 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1 | NCT00754780 | Neurofibromatos... | Pirfenidone | 18 Years - 70 Years | Mayo Clinic | |
| Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas | NCT01275586 | Neurofibromatos... NF1 Neurofibromas | Tasigna | 18 Years - | Indiana University | |
| Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas | NCT00716469 | Neurofibroma | LS11 | 3 Years - 21 Years | Children's Hospital of Philadelphia | |
| Individual Patient Compassionate Use of Mirdametinib | NCT05028166 | Neurofibromatos... Histiocytic Neo... Other MAP-K Pat... | Mirdametinib (M... | 2 Years - | SpringWorks Therapeutics, Inc. | |
| Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas | NCT05253131 | MPNST NF1 Sarcoma | Selumetinib | 18 Years - 99 Years | University of Alabama at Birmingham | |
| Natural History Study of Patients With Neurofibromatosis Type I | NCT00924196 | Neurofibromatos... Malignant Perip... Plexiform Neuro... Optic Glioma Neurofibroma | 4 Weeks - | National Institutes of Health Clinical Center (CC) | ||
| DPCP to Treat Cutaneous Neurofibromas Associated With NF1 | NCT05438290 | Cutaneous Neuro... | DPCP | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I | NCT00684398 | Neurofibromatos... Von Recklinghau... NF1 | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Natural History Study of Cutaneous Neurofibromas in People With NF1 | NCT05581511 | Neurofibromatos... Neurofibromatos... Neurofibromatos... Cutaneous Neuro... | Evaluation of t... | 1 Year - 100 Years | Johns Hopkins University | |
| Feasibility and Clinically Application of Magnetic Resonance Fingerprinting | NCT02387840 | Neurofibromatos... Brain Tumor Glioma | Magnetic Resona... Magnetic Resona... | - 35 Years | Case Comprehensive Cancer Center | |
| Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST) | NCT06222203 | Neurofibromatos... Nerve Sheath Ne... | 3 Years - 120 Years | National Institutes of Health Clinical Center (CC) | ||
| Neurofibromatosis (NF) Registry Portal | NCT01885767 | Neurofibromatos... Neurofibromatos... Schwannomatosis | - | The Children's Tumor Foundation | ||
| DPCP to Treat Cutaneous Neurofibromas Associated With NF1 | NCT05438290 | Cutaneous Neuro... | DPCP | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Reading Disability in Children With NF1 | NCT02397967 | Neurofibromatos... | Neuropsychologi... | 8 Years - 12 Years | University Hospital, Toulouse | |
| Microarray CGH Analysis of Circulating Tumoral Plasma DNA in NF1 Patients With MPNSTs | NCT01218152 | Neurofibromatos... | - | KU Leuven | ||
| Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1) | NCT00352599 | Neurofibromatos... | Lovastatin Lovastatin placebo pill | 10 Years - 50 Years | University of California, Los Angeles | |
| Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1 | NCT05238909 | Neurofibromatos... NF1 Neurofibromatos... | - | Ann & Robert H Lurie Children's Hospital of Chicago | ||
| Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery | NCT02315625 | Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Carcinoma, Neur... Neuroendocrine ... | Sunitinib Everolimus | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST) | NCT06222203 | Neurofibromatos... Nerve Sheath Ne... | 3 Years - 120 Years | National Institutes of Health Clinical Center (CC) | ||
| Natural History Study of Patients With Neurofibromatosis Type I | NCT00924196 | Neurofibromatos... Malignant Perip... Plexiform Neuro... Optic Glioma Neurofibroma | 4 Weeks - | National Institutes of Health Clinical Center (CC) | ||
| A Phase II Trial of Poly-ICLC for Low-Grade Gliomas | NCT04544007 | NF1 Low-grade Gliom... | Poly ICLC | - 22 Years | University of Alabama at Birmingham | |
| A Study of Avutometinib for People With Solid Tumor Cancers | NCT06104488 | Refractory Canc... CNS Tumors CNS Tumor, Adul... CNS Tumor, Chil... MAP Kinase Fami... NF1 Plexiform Neuro... Low-grade Gliom... Optic Pathway G... Neuroblastoma Primary Brain T... Solid Tumor Solid Tumor, Ad... Solid Carcinoma Central Nervous... | Avutometinib | 3 Years - 30 Years | Memorial Sloan Kettering Cancer Center | |
| Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach. | NCT02777775 | Cutaneous Neuro... Neurofibromatos... Plexiform Neuro... | Skin Biopsy | 18 Years - | Spectrum Health Hospitals | |
| Multi-center Project: Spinal Abnormalities in Neurofibromatosis Type1 (NF1) Patients | NCT00667836 | Neurofibromatos... | 3 Years - 18 Years | Shriners Hospitals for Children | ||
| Study of Plexiform Neurofibromas in Neurofibromatosis Type 1 | NCT00006435 | Plexiform Neuro... NF1 | - 100 Years | National Institutes of Health Clinical Center (CC) | ||
| Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults | NCT02101736 | NF1 Neurofibromatos... Plexiform Neuro... | Cabozantinib | 3 Years - | University of Alabama at Birmingham | |
| Interventions for Reading Disabilities in NF1 | NCT02964884 | Neurofibromatos... Learning Disabi... Reading Disabil... NF1 | Lovastatin reading tutorin... Placebo Oral Ta... Other Academic ... | 8 Years - 20 Years | Vanderbilt University | |
| Neurofibromatosis Type 1 Patient Registry | NCT01410006 | Neurofibromatos... | - | Washington University School of Medicine | ||
| Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas | NCT01275586 | Neurofibromatos... NF1 Neurofibromas | Tasigna | 18 Years - | Indiana University | |
| Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With NF1 | NCT01058330 | Neurofibromatos... | Plyometric trai... | 4 Years - 19 Years | Shriners Hospitals for Children | |
| Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas | NCT04924608 | Neurofibromatos... Plexiform Neuro... | Selumetinib Placebo | 18 Years - | AstraZeneca | |
| Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 | NCT04954001 | Neurofibromatos... Plexiform Neuro... NF1 | FCN-159 | 2 Years - 70 Years | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | |
| R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas | NCT00021541 | Neurofibroma, P... Neurofibromatos... | tipifarnib placebo | 3 Years - 25 Years | National Institutes of Health Clinical Center (CC) | |
| Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 | NCT04954001 | Neurofibromatos... Plexiform Neuro... NF1 | FCN-159 | 2 Years - 70 Years | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | |
| AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors | NCT01362803 | Neurofibromatos... Neurofibromatos... NF1 Neurofibroma, P... | AZD6244 | 2 Years - 18 Years | National Institutes of Health Clinical Center (CC) | |
| A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1 | NCT06262113 | Neurofibromatos... | Letters about N... Letters about N... | 18 Years - | Massachusetts General Hospital | |
| US Selumetinib Registry | NCT05683678 | Neurofibromatos... Plexiform Neuro... | 2 Years - 18 Years | Alexion Pharmaceuticals, Inc. | ||
| Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II | NCT02728388 | NEUROFIBROMATOS... | aminolevulinic ... | 14 Years - 30 Years | Medical College of Wisconsin | |
| Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas | NCT00727233 | Neurofibromatos... Plexiform Neuro... | Nexavar (BAY 43... Toxicity, Pharm... Pharmacodynamic... Radiographic Ev... QOL assessment,... Bony Toxicity | 3 Years - 18 Years | National Institutes of Health Clinical Center (CC) | |
| Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1 | NCT00314119 | Neurofibromatos... Neurofibroma | 20 Years - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 | NCT04954001 | Neurofibromatos... Plexiform Neuro... NF1 | FCN-159 | 2 Years - 70 Years | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | |
| Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF). | NCT06159166 | NF1 Cutaneous Neuro... Monotherapy | Mirdametinib | 18 Years - | Johns Hopkins University | |
| FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas | NCT05913037 | Neurofibromatos... Plexiform Neuro... NF1 | Test group (Gro... Control group (... | 18 Years - 70 Years | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | |
| Individual Patient Compassionate Use of Mirdametinib | NCT05028166 | Neurofibromatos... Histiocytic Neo... Other MAP-K Pat... | Mirdametinib (M... | 2 Years - | SpringWorks Therapeutics, Inc. | |
| AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors | NCT01362803 | Neurofibromatos... Neurofibromatos... NF1 Neurofibroma, P... | AZD6244 | 2 Years - 18 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 (NF1) | NCT02718131 | NF1 Congenital Pseu... | INFUSE Bone Gra... Control Group | 2 Years - 18 Years | University of Alabama at Birmingham | |
| Effect of Lamotrigine on Cognition in NF1 | NCT02256124 | Neurofibromatos... | Lamotrigine Placebo | 12 Years - 18 Years | Erasmus Medical Center | |
| Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults | NCT02101736 | NF1 Neurofibromatos... Plexiform Neuro... | Cabozantinib | 3 Years - | University of Alabama at Birmingham | |
| Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1) | NCT00111384 | Neurofibromatos... Legius Syndrome | 2 Years - 100 Years | National Institutes of Health Clinical Center (CC) | ||
| Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas | NCT00716469 | Neurofibroma | LS11 | 3 Years - 21 Years | Children's Hospital of Philadelphia | |
| US Selumetinib Registry | NCT05683678 | Neurofibromatos... Plexiform Neuro... | 2 Years - 18 Years | Alexion Pharmaceuticals, Inc. | ||
| Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach. | NCT02777775 | Cutaneous Neuro... Neurofibromatos... Plexiform Neuro... | Skin Biopsy | 18 Years - | Spectrum Health Hospitals | |
| Multi-center Project: Spinal Abnormalities in Neurofibromatosis Type1 (NF1) Patients | NCT00667836 | Neurofibromatos... | 3 Years - 18 Years | Shriners Hospitals for Children | ||
| Neurofibromatosis Type 1 Patient Registry | NCT01410006 | Neurofibromatos... | - | Washington University School of Medicine | ||
| Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery | NCT02315625 | Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Carcinoma, Neur... Neuroendocrine ... | Sunitinib Everolimus | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I | NCT00684398 | Neurofibromatos... Von Recklinghau... NF1 | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Feasibility and Clinically Application of Magnetic Resonance Fingerprinting | NCT02387840 | Neurofibromatos... Brain Tumor Glioma | Magnetic Resona... Magnetic Resona... | - 35 Years | Case Comprehensive Cancer Center | |
| Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas | NCT00727233 | Neurofibromatos... Plexiform Neuro... | Nexavar (BAY 43... Toxicity, Pharm... Pharmacodynamic... Radiographic Ev... QOL assessment,... Bony Toxicity | 3 Years - 18 Years | National Institutes of Health Clinical Center (CC) | |
| Reading Disability in Children With NF1 | NCT02397967 | Neurofibromatos... | Neuropsychologi... | 8 Years - 12 Years | University Hospital, Toulouse | |
| Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas | NCT01158651 | Glioma | RAD001 (Everoli... | 1 Year - 21 Years | University of Alabama at Birmingham |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
